Source: Annual Congress 2009 - Towards improving asthma control
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Máspero, I. Chérrez, H. Nolte (Buenos Aires, Argentina; Guayaquil, Ecuador; Kenilworth, United States Of America). Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial. Eur Respir J 2009; 34: Suppl. 53, 274

Member's Comments

No comment yet.

Related content which might interest you: Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function Source: Eur Respir J 2012; 39: 279-289 Year: 2012 Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012 The efficacy of salmeterol/fluticasone (SF) for 6-month therapy in severe COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 30s Year: 2006 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Fluticasone/salmeterol combination (FP/S) for immediate post-exacerbation treatment of childhood asthma Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: Results from the IRIDIUM study Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021